A compound that has the ability to reduce oxidative damage has the potential to slow the progression of Huntington's disease, according to a new study.
Researchers at the University of Rochester Medical Centre claim that Coenzyme Q10 (CoQ) acts as an antioxidant in patients with Huntington's disease and requires further study.
Dr Kevin M Biglan, lead author of the study, also stresses that the discovery enables scientists to better evaluate the potential of new treatments by identifying a new biomarker for neurological conditions.
The efficacy of CoQ was identified when researchers evaluated the blood samples of 20 people with Huntington's disease who had undergone treatment with CoQ in a previous clinical trial.
It was observed that in addition to improving the appearance of some symptoms of the condition, it had an effect on a molecular level in the brain, dropping the levels of a genetic code malfunction known to cause Huntington's by 20 per cent.
The findings coincide with the announcement that a new device implanted in the brains of those with Huntington's disease could have a restorative effect for patients. However, further testing is needed.
Find out how Barchester works to create safe and understanding environments for those living with Huntington's Disease.